DESolve Post-Approval Study
POST-MARKET EVALUATION OF DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
Sponsor: Elixir Medical Corporation
A NA clinical study on Coronary Artery Disease, this trial is completed. The trial is conducted by Elixir Medical Corporation and has accumulated 10 data snapshots since 2014. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
May 2020 — Jan 2021 [monthly]
Completed NA
-
Aug 2019 — May 2020 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Aug 2018 — Aug 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting NA
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting · Phase: PHASE4 → NA
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Elixir Medical Corporation
For direct contact, visit the study record on ClinicalTrials.gov .